Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody\u00ae iSCIB1+

• click to rate

  Posted by Two Blokes Jul 22 - Filed in Stock - 6 views
  
  SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety